Grifols

🇪🇸Spain

Country: 🇪🇸Spain

Ownership: Subsidiary, Public

Established: 1940-01-01

Employees: 23.7K

Market Cap: $6.8B

Website: http://www.grifols.com

Introduction: Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.

Clinical Trials

Efficacy and Safety of Fanhdi®, a High-purity Von Willebrand Containing FVIII Concentrate, in Pediatric Patients With Von Willebrand Disease

Phase 4

Recruiting

Conditions: Von Willebrand Disease

Interventions: Drug: plasma-derived FVIII/VWF concentrate

First Posted Date: 2015-06-16

Last Posted Date: 2024-07-08

Lead Sponsor: Grifols Therapeutics LLC

Target Recruit Count: 8

Registration Number: NCT02472665

Locations: 🇪🇸
Hospital Universitario Virgen del Rocío, Sevilla, Spain
🇪🇸
Hospital Universitario Miguel Servet, Zaragoza, Spain
🇪🇸
Hospital Sant Joan de Déu Barcelona, Esplugues De Llobregat, Barcelona, Spain

and more 1 locations

A Study to Assess the Efficacy and Safety of IGIV-C in Patients With Myasthenia Gravis Exacerbations

Phase 3

Completed

Conditions: Myasthenia Gravis Exacerbations

Interventions: Biological: IGIV-C

First Posted Date: 2015-04-10

Last Posted Date: 2020-04-24

Lead Sponsor: Grifols Therapeutics LLC

Target Recruit Count: 49

Registration Number: NCT02413580

Locations: 🇦🇷
Hospital Italiano, Buenos Aires, Argentina
🇦🇷
Hospital General de Agudos Dr. J. M., Buenos Aires, Argentina
🇭🇺
Jahn Ferenc Del-Pesti Korhaz, Budapest, Hungary

and more 28 locations

A Study to Assess Safety and PK of Liquid Alpha₁-Proteinase Inhibitor (Human) in Treating Alpha₁-Antitrypsin Deficiency

Phase 2

Completed

Conditions: Alpha₁-Antitrypsin Deficiency

Interventions: Biological: Liquid Alpha₁-PI
Biological: Prolastin-C

First Posted Date: 2014-11-04

Last Posted Date: 2017-03-13

Lead Sponsor: Grifols Therapeutics LLC

Target Recruit Count: 32

Registration Number: NCT02282527

Locations: 🇺🇸
University of Miami - Miller School of Medicine, Miami, Florida, United States
🇺🇸
National Jewish Health, Denver, Colorado, United States
🇺🇸
PMG Research of Wilmington, Wilmington, North Carolina, United States

and more 3 locations

Pharmacokinetics, Efficacy, and Safety of Human Plasma-Derived Fibrinogen (FIB Grifols) in Participants With Congenital Afibrinogenemia

Phase 1

Completed

Conditions: Congenital Afibrinogenemia

Interventions: Biological: Human Plasma-Derived Fibrinogen Concentrate

First Posted Date: 2014-11-02

Last Posted Date: 2022-03-31

Lead Sponsor: Grifols Therapeutics LLC

Target Recruit Count: 24

Registration Number: NCT02281500

Locations: 🇺🇸
Northshore Long Island Jewish Medical Center, New Hyde Park, New York, United States
🇮🇹
Agenzia per l'Emofilia Centro di Riferimento Regionale per le Coaugulopatie Congenite A.O. di Carreggi, Firenze, Italy
🇱🇧
Hôtel-Dieu de France Hospital, Beirut, Lebanon

and more 3 locations

An Open-label, Single-Arm Study to Evaluate the Safety and Rabies Virus Antibody Titers of Intramuscularly Administered Rabies Immune Globulin (Human)

Phase 1

Completed

Conditions: Rabies

Interventions: Biological: RIG-C

First Posted Date: 2014-05-15

Last Posted Date: 2014-07-24

Lead Sponsor: Grifols Therapeutics LLC

Target Recruit Count: 12

Registration Number: NCT02139657

Study of Human Plasma-Derived Alpha1-Proteinase Inhibitor in Subjects With New-Onset Type 1 Diabetes Mellitus

Phase 2

Terminated

Conditions: Type 1 Diabetes Mellitus

Interventions: Biological: Placebo
Biological: 90 mg/kg Alpha1-PI
Biological: 180 mg/kg Alpha1-PI

First Posted Date: 2014-03-20

Last Posted Date: 2018-09-05

Lead Sponsor: Grifols Therapeutics LLC

Target Recruit Count: 76

Registration Number: NCT02093221

Locations: 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸
Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸
Endocrinology Associates Inc, Columbus, Ohio, United States

and more 33 locations

Safety and Efficacy of Preoperative Antithrombin Supplementation in Patients Undergoing High-Risk Cardiopulmonary Bypass

Phase 2

Completed

Conditions: Cardiopulmonary Bypass
Cardiac Surgery

Interventions: Other: Placebo
Biological: AT-III (Human)

First Posted Date: 2014-01-16

Last Posted Date: 2019-03-15

Lead Sponsor: Grifols Therapeutics LLC

Target Recruit Count: 425

Registration Number: NCT02037555

Locations: 🇺🇸
University Hospitals Case Medical Center, Cleveland, Ohio, United States
🇺🇸
Summa Health Hospital, Akron, Ohio, United States
🇺🇸
The Ohio State University Wexner Medical Center, Columbus, Ohio, United States

and more 38 locations

Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD)

Phase 3

Active, not recruiting

Conditions: Pulmonary Emphysema in Alpha-1 PI Deficiency

Interventions: Other: 0.9% Sodium Chloride for Injection, USP
Biological: Alpha-1 MP

First Posted Date: 2013-11-13

Last Posted Date: 2025-01-15

Lead Sponsor: Grifols Therapeutics LLC

Target Recruit Count: 345

Registration Number: NCT01983241

Locations: 🇲🇩
Institutul de Ftiziopneumologie "Chiril Draganiuc", Chisinau, Moldova, Republic of
🇺🇸
St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

and more 49 locations

Safety and Tolerability Trial of Inhaled Alpha1-Proteinase Inhibitor (Human), Hydrophobic Chromatography Process (Alpha-1 HC) in Subjects With Cystic Fibrosis

Phase 2

Completed

Conditions: Cystic Fibrosis

Interventions: Biological: Alpha-1 HC 200 mg
Biological: Placebo
Biological: Alpha-1 HC 100 mg

First Posted Date: 2012-09-13

Last Posted Date: 2016-02-08

Lead Sponsor: Grifols Therapeutics LLC

Target Recruit Count: 30

Registration Number: NCT01684410

Locations: 🇺🇸
The University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States
🇺🇸
UNC at Chapel Hill, Chapel Hill, North Carolina, United States

and more 3 locations

Pharmacokinetics, Safety, and Tolerability of Subcutaneous GAMUNEX-C in Pediatric Subjects With Primary Immunodeficiency

Phase 4

Completed

Conditions: Primary Immunodeficiency

Interventions: Biological: GAMUNEX-C

First Posted Date: 2011-11-06

Last Posted Date: 2015-03-13

Lead Sponsor: Grifols Therapeutics LLC

Target Recruit Count: 12

Registration Number: NCT01465958

Locations: 🇺🇸
IMMUNOe International Research Centers, Centennial, Colorado, United States
🇺🇸
Childrens Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
Joe DiMaggio Children's Hospital, Hollywood, Florida, United States

and more 1 locations

Home Terms & Conditions Privacy Policy